Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.25 Average Target Price from Brokerages

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $6.25.

A number of equities analysts recently issued reports on the stock. Needham & Company LLC decreased their target price on shares of Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. JMP Securities reiterated a “market outperform” rating and set a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. The Goldman Sachs Group cut their target price on Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Friday, April 25th.

Esperion Therapeutics Price Performance

Shares of ESPR stock opened at $0.86 on Friday. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $3.94. The firm has a market capitalization of $171.22 million, a price-to-earnings ratio of -1.35 and a beta of 0.75. The business has a 50 day simple moving average of $1.14 and a 200 day simple moving average of $1.82.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The firm had revenue of $65.00 million during the quarter, compared to the consensus estimate of $54.97 million. On average, equities analysts anticipate that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Institutional Trading of Esperion Therapeutics

Large investors have recently added to or reduced their stakes in the company. Summit Financial LLC lifted its stake in Esperion Therapeutics by 18.2% in the 4th quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 7,150 shares in the last quarter. Foundations Investment Advisors LLC grew its position in Esperion Therapeutics by 48.6% during the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 9,872 shares in the last quarter. Private Advisor Group LLC increased its stake in Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company’s stock valued at $58,000 after buying an additional 10,000 shares during the period. Invesco Ltd. lifted its position in Esperion Therapeutics by 15.5% in the 4th quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 13,101 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its position in Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after buying an additional 16,100 shares in the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.